New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MRK;PFE;GSK;JNJ;BMY;NVS;SHPG;ABT;CELG;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
July 23, 2015
17:51 EDTJNJJanssen submits sNDA to update label for Olysio
Subscribe for More Information
14:01 EDTSHPGShire receives 'positive opinion' on Intuniv from CHMP
Shire announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of the once-daily, non-stimulant Intuniv, or guanfacine hydrochloride extended release, for the treatment of attention deficit/hyperactivity disorder in children and adolescents. The positive opinion is based on results from three Phase 3 pivotal studies investigating the short- and long-term safety and efficacy of Intuniv in children and adolescents. The European Commission will now consider the CHMP positive opinion in its decision of whether to grant marketing authorisation for Intuniv in Europe, said Shire.
11:04 EDTMRKMerck announces EMA acceptance of MAA for grazoprevir/elbasvir
Subscribe for More Information
10:50 EDTCELGCelgene positioned for sustainable growth, says Piper Jaffray
Subscribe for More Information
07:37 EDTCELGCelgene reports Q2 Revlimid sales up 19% to $1.44B
ABRAXANE® sales for the second quarter were $244 million, a 13 percent increase. POMALYST®/IMNOVID® sales for the second quarter were $235 million, an increase of 46%. VIDAZA® sales in the second quarter remained flat year-over-year at $152 million. OTEZLA® sales for the second quarter were $90 million, increasing 49 percent over the first quarter of 2015.
07:37 EDTCELGCelgene raises FY15 adjusted EPS view to $4.75-$4.85 from $4.60-$4.75
Subscribe for More Information
07:34 EDTBMYBristol-Myers raises FY15 adjusted EPS view to $1.70-$1.80 from $1.60-$1.70
Subscribe for More Information
07:32 EDTCELGCelgene reports Q2 adjusted EPS $1.23, consensus $1.20
Subscribe for More Information
07:31 EDTBMYBristol-Myers reports Q2 EPS 53c, consensus 36c
Subscribe for More Information
07:25 EDTSHPGShire raises FY15 EPADS growth view to mid-to-high single digit percentage
Subscribe for More Information
07:22 EDTSHPGShire reports Q2 EPS $2.63, consensus $2.81
Subscribe for More Information
06:38 EDTBMYBristol-Myers' two Opdivo applications validated by European Medicines Agency
Subscribe for More Information
July 22, 2015
15:26 EDTBMY, CELGNotable companies reporting before tomorrow's open
Subscribe for More Information
10:15 EDTJNJThoratec downgraded to Market Perform from Outperform at Northland
Subscribe for More Information
10:06 EDTABTAbbott CEO says supportive of Mylan pursuit of Perrigo
Subscribe for More Information
09:33 EDTABTAbbott sees Q3 Diagnostics sales up mid single digits on operational basis
Subscribe for More Information
09:30 EDTABTAbbott CEO says 'pretty alligned' with Mylan so far
09:28 EDTCELGBiogen downgraded to Neutral at Piper Jaffray after Alzheimer's data
Subscribe for More Information
09:15 EDTABTAbbott sees FY15 reported sales growth to be in low single digits
Subscribe for More Information
09:15 EDTABTAbbott sees Q3 EPS 52c-54c, consensus 55c
Sees Q3 impact from foreign exchange to be "somewhat above" 9% based on current exchange rates, resulting in reported sales growth in the low single digits, consensus $5.19B. Guidance from Q2 earnings call.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use